Version 1
: Received: 3 November 2020 / Approved: 4 November 2020 / Online: 4 November 2020 (10:08:38 CET)
How to cite:
Astolpho, V.; Barbosa, R.; Devens, G.; Louzada, L.; Lima, P.; Sylvestre, R.; Serpa, R.; Calil, O.; Barbosa, L.F. Prognostic Value of the Six-Minute Walk Test in Heart Failure. Preprints2020, 2020110185. https://doi.org/10.20944/preprints202011.0185.v1
Astolpho, V.; Barbosa, R.; Devens, G.; Louzada, L.; Lima, P.; Sylvestre, R.; Serpa, R.; Calil, O.; Barbosa, L.F. Prognostic Value of the Six-Minute Walk Test in Heart Failure. Preprints 2020, 2020110185. https://doi.org/10.20944/preprints202011.0185.v1
Astolpho, V.; Barbosa, R.; Devens, G.; Louzada, L.; Lima, P.; Sylvestre, R.; Serpa, R.; Calil, O.; Barbosa, L.F. Prognostic Value of the Six-Minute Walk Test in Heart Failure. Preprints2020, 2020110185. https://doi.org/10.20944/preprints202011.0185.v1
APA Style
Astolpho, V., Barbosa, R., Devens, G., Louzada, L., Lima, P., Sylvestre, R., Serpa, R., Calil, O., & Barbosa, L.F. (2020). Prognostic Value of the Six-Minute Walk Test in Heart Failure. Preprints. https://doi.org/10.20944/preprints202011.0185.v1
Chicago/Turabian Style
Astolpho, V., Osmar Calil and Luiz Fernando Barbosa. 2020 "Prognostic Value of the Six-Minute Walk Test in Heart Failure" Preprints. https://doi.org/10.20944/preprints202011.0185.v1
Abstract
Background: The 6-minute walk test (6MWT) is a simple and low-cost method that allows assessment of functional capacity in patients with heart failure (HF). However, the prognostic role of 6MWT in HF remains uncertain. Objectives: We aimed to evaluate the 6MWT as a predictor of mid-term adverse outcomes in patients with HF with mid-range and reduced ejection fraction. Methods: Prospective single-center cohort study that included patients with HF with an ejection fraction under 50% at a specialized outpatient HF service. Patients underwent the 6MWT on admission and were compared according to the distance walked: Group I walked ≥350 meters and group II <350 meters. The primary outcome was a composite of death from any cause or hospitalization for HF decompensation in one-year follow-up. Secondary outcomes were the components of the primary outcome in an isolated analysis. Results: Sixty patients were included, 43.3% male, with a mean age of 61.1 ± 12.9 years and ejection fraction 34.3 ± 10.1%. 52 patients (86.7%) were on guideline-directed triple therapy for HF. The average distance walked in the 6MWT was 395.1 ± 98.8 meters, with 40 patients (66.7%) in group I and 20 (33.3%) in group II. The primary outcome in groups I and II were, respectively, 15,0% and 35,0% (p=0.05). One-year mortality was 5.0% vs 15.0% (p=0.18) and the hospitalization rate was 10.0% vs 20.0% (p=0.28). Conclusions: There was no association of distance <350 meters in the 6MWT with the primary outcome in patients with HF. Despite the higher occurrence of outcomes in group II, the difference was not statistically significant in this analysis. On a selective basis, the 6MWT may be a useful tool for prognostic stratification in HF, if combined with other methods.
Keywords
heart failure; 6-minute walk test; prognosis
Subject
Medicine and Pharmacology, Immunology and Allergy
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
